/
RNA
$13.45-$0.20 (-1.47%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$225.6M
17M shares
52-week range
$11.40 – $73.06
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.09%
Moderate
Price (6 mo)
Loading chart…
Change$-10.35
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2025 | |
|---|---|
| Revenue | $18.6M |
| Cost of revenue | $0 |
| Gross profit | $18.6M |
| Gross margin | 100.0% |
| R&D | $53.8M |
| Operating income | −$76.8M |
| EBITDA | −$76.5M |
| Net income | −$76.7M |
| Net margin | -411.9% |
| EPS (diluted) | -4.48 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $22M | $-4.70 | $-8.23–$-1.88 | 4 |
| 2027 | $3M | $-5.61 | $-5.67–$-5.54 | 3 |
| 2028 | $4M | $-6.08 | $-14.99–$6.57 | 6 |
| 2029 | $1.6B | $-4.50 | $-7.88–$-1.80 | 4 |
Forward consensus · source: Financial Modeling Prep
Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
www.aviditybiosciences.com- Employees
- 391
- IPO / List date
- Feb 27, 2026
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds RNA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in RNA as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded RNA yet.
